Benign hereditary chorea and deletions outside \textit{NKX2-1}: What's the role of \textit{MBIP}?

Federica Invernizzi, Giovanna Zorzi, Andrea Legati, Giovanni Coppola, Pio D'Adamo, Nardo Nardocci, Barbara Garavaglia, Daniele Ghezzi

PII: S1769-7212(17)30765-6
DOI: 10.1016/j.ejmg.2018.03.011
Reference: EJMG 3439

To appear in: \textit{European Journal of Medical Genetics}

Received Date: 23 November 2017
Revised Date: 9 February 2018
Accepted Date: 27 March 2018


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Clinical research paper

Benign Hereditary Chorea and deletions outside NKX2-1: what’s the role of MBIP?

Federica Invernizzi\textsuperscript{a}, Giovanna Zorzi\textsuperscript{b}, Andrea Legati\textsuperscript{a}, Giovanni Coppola\textsuperscript{c}, Pio D’Adamo\textsuperscript{d,e}, Nardo Nardocci\textsuperscript{b}, Barbara Garavaglia\textsuperscript{a}, Daniele Ghezzi\textsuperscript{a,f}

\textsuperscript{a}Molecular Neurogenetics, \textsuperscript{b}Child Neurology Unit, Foundation IRCCS Neurological Institute Besta, Milan, Italy
\textsuperscript{c}Departments of Psychiatry and Neurology, University of California, Los Angeles, CA, USA
\textsuperscript{d}Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, Trieste, Italy
\textsuperscript{e}Clinical Department of Medical, Surgical and Health Science, University of Trieste, Italy
\textsuperscript{f}Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Correspondence to: Daniele Ghezzi
Molecular Neurogenetics Unit, Foundation IRCCS Neurological Institute “Besta”, via Temolo 4, 20126 Milan, Italy; Tel: +39 0223942627; Fax: +39 0223942619; daniele.ghezzi@istituto-besta.it

Abstract

Heterozygous point mutations or deletions of the NKX2-1 gene cause benign hereditary chorea (BHC) or a various combinations of primary hypothyroidism, respiratory distress and neurological disorders. Deletions proximal to, but not encompassing, NKX2-1 have been described in few subjects with brain-lung-thyroid syndrome. We report on a three-generation Italian family, with 6 subjects presenting BHC and harboring a genomic deletion adjacent to NKX2-1 and including the gene MBIP, recently proposed to be relevant for the pathogenesis of brain-lung-thyroid syndrome. We observed a clear reduction of NKX2-1 transcript levels in fibroblasts from our patients compared to controls; this finding suggests that MBIP deletion affects NKX2-1 expression, mimicking haploinsufficiency caused by classical NKX2-1 related mutations.

Keywords: NKX2-1; MBIP; Benign Hereditary Chorea; brain-lung-thyroid syndrome
Introduction

Several NKX2-1 point mutations or deletions of chromosome 14 encompassing NKX2-1 have been associated with Benign Hereditary Chorea (BHC) [Breedveld et al. 2002; Thorwarth et al. 2014; Peall & Kurian 2015]. All patients were heterozygous for the mutation, therefore suggesting a dominant mode of inheritance. NKX2-1 encodes a transcription factor, which is expressed during early development of thyroid, lung and forebrain regions. Accordingly, in addition to BHC, patients with NKX2-1 mutations presented combinations of primary hypothyroidism, respiratory distress and neurological disorders. Few cases with BHC or brain-lung-thyroid syndrome have been reported to harbor deletions proximal to, but not disrupting, NKX2-1 [Barnett et al. 2012; Thorwarth et al. 2014; Kharbanda et al. 2017].

Here we describe a three-generation Italian family, with 6 subjects presenting with BHC and harboring a genomic deletion adjacent to NKX2-1 and including the gene MBIP, recently proposed to be relevant for the pathogenesis of brain-lung-thyroid syndrome [Kharbanda et al. 2017].

Patients’ Data

The probands were two siblings (III-1 and III-2, pedigree in Figure 1) with a very similar clinical picture (Table 1) consisting of hypotonia and motor delay, a hyperkinetic movement disorder noted since infancy and recurrent pulmonary infections. They both presented dysmorphic features (macrocephaly, prominent and large forehead, big round eyes, bilateral hallux valgus), oculomotor apraxia and generalized chorea with superimposed irregular myoclonic jerks. Cognitive functions were within normal limits. A younger half-sister (III-3) was referred for motor delay and unbalanced gait with frequent falls at age 4. The father (II-3) was affected by an early-onset, non progressive chorea and pulmonary pathology (severe asthma); after age 30, he suffered episodes of hypotension and hypoglycaemia. His brother (II-5) presented mild chorea associated with minor cognitive and psychiatric involvement; at age 35 he was diagnosed with lung carcinoma. Their grandmother (I-1) had only a mild early-onset chorea and she did not experience any pulmonary disease.

Thyroid function was measured in all cases during the follow-up and always resulted normal. The movement disorder spontaneously improved over time in all cases, causing little or no functional disability.

Methods

Informed consent for the genetic diagnosis was obtained from patients or parents according to the local regulations, DNA was extracted from venous peripheral blood lymphocytes according to standard procedures and was used as a template to amplify the 3 exons of the NKX2-1 gene. PCR
fragments were analyzed by automated nucleotide sequencing using the Big-Dye terminator Ready Reaction Kit version 2 on a 3100 Genetic Analyzer Automated Sequencer (Applied Biosystems). Haplotype analysis was performed by SNPs array (ILLUMINA HumanCytoSNP-12 BeadChip). For whole exome sequencing (WES), genomic DNA was processed for library enrichment according to the SeqCap EZ Exome v3.0 kit (Roche). Sequencing was performed on an Illumina® Genome Analyzer HiSeq2500. The sequencing reads were aligned to the National Center for Biotechnology Information human reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA). Variant calling was performed using Genome Analysis Toolkit (GATK) and VariantStudio Data Analysis Software (Illumina®) was used for variants annotation and filtering. Coverage analysis was performed on WES data of individuals I-1 and III-2 using CANOES (http://www.columbia.edu/~ys2411/canoes). CANOES is a bioinformatics tool based on an algorithm for the detection of rare copy number variants from exome sequencing data; it uses a regression-based approach on selected reference samples in a given dataset to estimates variance of the read counts for an affected sample.

For gene content analysis, real-time quantitative PCR (RT-qPCR) was performed using SYBR Green chemistry and primers specific to MBIP exon 1 and 8, with a single copy gene (RNaseP) taken as a nuclear gene reference. For the analysis of transcripts, total RNA was extracted from fibroblasts patient, according to the manufacturer’s instructions (RNeasy Mini Kit Qiagen). RT-qPCR assay on cDNA (Go Taq® 2 step RTqPCR System) was performed using three different primers specific for amplification of NKX2-1 and and one house-keeping gene (ACTB).

**Results**

Because of the clinical presentation, we sequenced NKX2-1 in the proband III-1 but no mutation was found. In order to identify the genetic defect, we performed SNP-array analysis and WES. SNP-array analysis on available DNAs from the family revealed a genomic deletion on chr14:36206651-36321589 [GRCh38/hg38] (LOVD Variant ID: 0000352599) in 5 affected family members, absent in two unaffected cases (Figure 1). The identified deletion was near NKX2-1, but not encompassing this gene. Only one gene, MBIP (encoding MAP3K12 binding inhibitory protein 1), was included in the deleted region (Figure 1). WES was performed on individuals I-1 and III-2. Filtering steps using chorea genes (NKX2-1, SGCE, SLC16A2, ADCY5) as a bait, did not identified any candidate variants shared by the two affected cases. Because of the negative results from WES and the published evidence that copy number changes in next proximity to NKX2-1 may cause a phenotype comparable to that of intragenic mutations [Kharbanda et al. 2017; Thorwarth et al. 2014], we pointed our attention to the chr14q13 deletion. We demonstrated the heterozygous deletion of MBIP in all affected members of the family (Figure 1) by quantitative PCR. Moreover, a
deep analysis of WES coverage data further confirmed this finding, highlighting that only MBIP has a halved copy number whereas the surrounding genes, including NKX2-1, were not affected (Supplementary Figure S1). In order to evaluate any possible effect of the MBIP deletion on NKX2-1 expression, we measured NKX2-1 transcript levels in patients II-3, III-1 and III-2. Despite the low expression of NKX2-1 in fibroblasts, we observed a clear reduction of NKX2-1 transcript levels in our patients compared to controls, although slightly lower than the decrease observed in fibroblasts from two patients harboring mutations in NKX2-1 (Supplementary Figure S2).

**Discussion**

The deletion we identified comprises a single gene, MBIP, not associated with any human disease. Notably, deletion of MBIP was present in all reported cases of 14q13 deletion adjacent to but not directly involving NKX2-1 [Barnett et al. 2012; Thorwarth et al. 2014; Kharbanda et al. 2017] (Figure 1).

All these data suggest two possible, non-exclusive, mechanisms: 1) MBIP impairment is directly related to the pathogenesis of BHC and other brain-lung-thyroid syndromes; 2) MBIP deletion affects genomic elements important for NKX2-1 expression, resulting in NKX2-1 impairment, as for the classical BHC cases.

Data in support of both hypotheses have been published. An identical pattern of temporal and spatial expression for MBIP and NKX2-1, including basal ganglia, forebrain, thyroid and lung, was reported [Thorwarth et al. 2014]; moreover, the chromosomal region encompassing the two genes is part of one of the largest synteny blocks in humans [Santagati et al. 2003]. These findings may indicate that both genes are important for the same biological process, i.e. the proper development and function of brain, lung and thyroid. Nevertheless, the known roles of MBIP protein seem not directly related or coincident to NKX2-1 and its expression regulation of thyroid-specific genes and genes involved in morphogenesis. Lastly, no point mutations in MBIP were found in 74 BHC patients, previously negative for NKX2-1 mutations [Thorwarth et al. 2014] or have ever been described, despite the wide and growing use of WES in several genetic diseases, including movement disorders [Singleton 2012], arguing against a direct role of MBIP dysfunction in BHC.

Conversely, our data from patients’ fibroblasts provide an experimental support to the hypothesis that a secondary impairment of NKX2-1, due to a deletion of the adjacent genomic region comprehending MBIP, mimics NKX2-1 haploinsufficiency and can explain the overlapping phenotype between deletions outside of NKX2-1 and intragenic NKX2-1 mutations.

Predicted enhancer elements for NKX2-1 have been reported in the deleted region of previous cases with BHC and without a direct involvement NKX2-1, suggesting that these elements could contribute to the observed phenotype and the impairment of NKX2-1 transcription we observed in
cells from our patients [Kharbanda et al. 2017]. Another possible explanation is that these deletions hit topologically associating domains (TADs), blocks of chromatin which are fundamental, not only for genome organization but also for genomic function [Dixon et al. 2016]. It has been shown that TADs play important roles in modulating transcription [Gorkin et al. 2014] and their disruption may result in disease [Lupianez et al. 2016]. The genomic region including *NKK2-1* and *MBIP* may be part of a TAD and deletion of portion of this domain could alter the expression of all or part of the contained genes.

In conclusion, our data indicate that deletion of the *MBIP* gene is associated with benign hereditary chorea, possibly lowering *NKK2-1* expression and thus mimicking haploinsufficiency caused by *NKK2-1* mutations.

The authors declare no conflict of interest.

**Acknowledgments**

The “Cell lines and DNA Bank of Genetic Movement Disorders and Mitochondrial Diseases” of the Telethon Network of Genetic Biobanks (grant GTB12001J) and the EuroBioBank Network supplied biological specimens. We acknowledge the support of the NINDS Informatics Center for Neurogenetics and Neurogenomics (P30 NS062691).

**Funding:** This work was supported by the Pierfranco and Luisa Mariani Foundation.

**Figure legend**

**Figure 1: Pedigree of the investigated family and genetic analyses**

A. SNP-array analysis, performed on all available DNAs from the family (8 subjects: 6 affected and 2 healthy cases), revealed a genomic heterozygous deletion on chr14q13 in 5 affected family members, absent in two unaffected cases. The poor quality of the DNA from individual I-1 led to its exclusion from the analysis. Real-time quantitative PCR showed the heterozygous deletion of *MBIP* on genomic DNAs in all affected members of the family. Labels indicate the presence (del) or absence (no_del) of the 14q13 deletion by SNP-array analysis (in dark blue) or the *MBIP* deletion by RT-qPCR (in red).

B. Map of the Chr.14 genomic region surrounding *MBIP* and *NKK2-1* genes, with the deletions identified in our family and in previously published cases.

**Table 1. Clinical features of the affected family members**
### Patient Neurological Respiratory Thyroid Psychiatric Other features

<table>
<thead>
<tr>
<th>Patient</th>
<th>Neurological</th>
<th>Respiratory</th>
<th>Thyroid</th>
<th>Psychiatric</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td>III-1</td>
<td>Hypotonia, generalized chorea, myoclonic jerks</td>
<td>Recurrent pulmonary infections</td>
<td>/</td>
<td>Mild cognitive impairment</td>
<td>Dysmorphisms</td>
</tr>
<tr>
<td>III-2</td>
<td>Hypotonia, generalized chorea, myoclonic jerks, ataxia</td>
<td>Recurrent pulmonary infections</td>
<td>/</td>
<td>/</td>
<td>Dysmorphisms, macrocrania</td>
</tr>
<tr>
<td>III-3</td>
<td>Motor delay, unbalanced gait</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>II-3</td>
<td>Chorea</td>
<td>Severe asthma</td>
<td>/</td>
<td>/</td>
<td>Hypotension, hypoglycaemia</td>
</tr>
<tr>
<td>II-5</td>
<td>Mild chorea</td>
<td>Lung carcinoma</td>
<td>/</td>
<td>Minor cognitive and psychiatric involvement</td>
<td>/</td>
</tr>
<tr>
<td>I-1</td>
<td>Mild chorea</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

### References


**Supplementary Material** includes 2 figures and is available online.

Supplementary Figure S1: Analysis of the coverage data from whole exome sequencing

Supplementary Figure S2: NKX2-1 transcript analysis
A

B

Present paper

Barnett et al. 2012
Thorwarth et al. 2014
Kharbanda et al. 2017